EP08.02-057 Mechanism of Resistance to Second-Line Aumolertinib and Therapeutic Regime after Resistance

Abstract

Aumolertinib is a novel, irreversible, 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with structure-predicted pharmacologic properties that selectively inhibit both EGFR sensitizing and resistance mutations. In phase II single-arm APOLLO study (NCT02981108), the most common mechanisms of resistance to Aumolertinib were acquired EGFR C797S mutation (26%) and aberration in PIK3CA bypass track(21%), which were different from AURA3(NCT02151981), where most common mechanisms of resistance to Osimertinib were MET amplification (19%) and acquired EGFR C797S mutation (15%).